Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 25th June 2018
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

EMA committee recommends first stem cell-based veterinary medicine
Arti-cell Forte is recommended for use in horses with mild to moderate lameness related to joint inflammation.
Arti-cell Forte indicated for use in horses with lameness

The first stem cell-based veterinary medicine has been recommended for marketing authorisation in the European Union by The European Medicines Agency's (EMA) Committee for Medicinal Products (CVMP).

Arti-cell Forte is recommended for use in horses with mild to moderate lameness related to joint inflammation. It is available as a suspension for injection and is given as a single injection into the affected joint.

In a press release, the EMA said the stem cells in the medicine are treated so they develop towards cartilage cells. This can then help to repair damaged cartilage in the joint.

‘In a field study conducted in horses with lameness of the fetlock joint, Arti-Cell Forte showed a statistically significant improvement in the horses treated with the medicine compared with a placebo control group six weeks after treatment,’ the EMA writes. ‘The positive effect of treatment was sustained over one year.’

Common side effects of the medicine reported in the study were mild increase in lameness and injection site reactions in the week following treatment.

The CVMP’s recommendation will now be passed on to the European Commission for a decision on an EU-wide marketing authorisation. 

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.